

EQA round: AP1/24 - Antithrombotic Agents

Deadline: 29.3.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL					
Set 1																
(108) Apixaban	[µg/L]				44									44	42	95
Sample A1		68,3	6,6	9,7	44		CVP	68,3	2,4	25%	51,2	85,4		44	42	95
(38) Werfen (IL)		72,7	5,3	7,2	14	0								14		
(94) Stago		61	8,9	15	7	0								7		
(149) Siemens (Dade, BN, Dimension)		66,8	4,1	6,1	13	0								13		
(179) Siemens		68,5	2,2	3,2	6	0								6		
Other					4	0								4		
							4x 193									
Sample B1		285	20	7	44		CVP	285	7,4	25%	213	357		44	44	100
(38) Werfen (IL)		283	10	3,7	14	0								14		
(94) Stago		289	11	3,9	7	0								7		
(149) Siemens (Dade, BN, Dimension)		288	30	10	13	0								13		
(179) Siemens		300	34	11	6	0								6		
Other					4	0								4		
							4x 193									
Set 2																
(109) Dabigatran	[µg/L]				36									36	35	97
Sample A2		54,2	5,8	11	36		CVP	54,2	2,3	30%	37,9	70,5		36	36	100
(38) Werfen (IL)		51	2,3	4,6	11	0								11		
(149) Siemens (Dade, BN, Dimension)		54,3	4,6	8,4	11	0								11		
(179) Siemens		51	4,4	8,7	5	0								5		
(193) HYPHEN BioMed		62,2	4,2	6,8	9	0								9		
Sample B2		214	30	14	36		CVP	214	12	30%	149	279		36	35	97
(38) Werfen (IL)		188	16	8,5	11	0								11		
(149) Siemens (Dade, BN, Dimension)		213	14	6,5	11	0								11		
(179) Siemens		210	6,7	3,2	5	0								5		
(193) HYPHEN BioMed		248	16	6,6	9	0								9		
Set 3																
(110) Rivaroxaban	[µg/L]				48									48	47	98
Sample A3		77,1	5,5	7,2	48		CVP	77,1	2	25%	57,8	96,4		48	47	98
(38) Werfen (IL)		80,5	4,8	5,9	15	0								15		
(94) Stago		71,5	8,2	11	7	0								7		
(149) Siemens (Dade, BN, Dimension)		76,4	3,9	5,2	14	0								14		
(179) Siemens		76	5,9	7,8	6	0								6		
(193) HYPHEN BioMed		76,3	3,4	4,5	5	0								5		
Other					1	0								1		
							1x 162									
Sample B3		304	21	7	48		CVP	304	7,6	25%	228	380		48	48	100
(38) Werfen (IL)		299	12	3,9	15	0								15		
(94) Stago		317	8,2	2,6	7	0								7		
(149) Siemens (Dade, BN, Dimension)		306	29	9,6	14	0								14		
(179) Siemens		300	30	9,9	6	0								6		
(193) HYPHEN BioMed		310	35	11	5	0								5		
Other					1	0								1		
							1x 162									